JEOL (6951) Q2 2027 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2027 earnings summary
13 Nov, 2026Executive summary
H1 FY2027 net sales were ¥65,817 million, down 19.8% YoY; operating profit was ¥5,193 million, down 56.5%, and net profit was ¥3,214 million, down 67.4%.
Orders received and backlog were the third- and second-highest levels on record, respectively, and both substantially exceeded prior-year levels.
FY2027 guidance remained unchanged at net sales of ¥164,000 million and operating profit of ¥26,500 million.
Financial highlights
Gross profit was ¥33,025 million versus ¥39,277 million; SG&A, including R&D, was ¥27,832 million versus ¥27,343 million.
Ordinary profit was ¥5,300 million versus ¥12,906 million; the prior-year period included a ¥971 million gain on sale of investment securities.
Yen depreciation added ¥2.7bn to operating profit; improved cost rate and lower R&D costs added ¥1.1bn and ¥0.9bn, while lower sales volume reduced profit by ¥10.1bn.
Net cash provided by operating activities increased to ¥10,853 million from ¥9,038 million.
Outlook and guidance
FY2027 forecasts: net sales ¥164,000 million, operating profit ¥26,500 million, ordinary profit ¥26,200 million and net profit ¥21,300 million; basic EPS ¥432.64.
Scientific and Measurement Instruments is expected to deliver YoY earnings growth, led by electron microscopes, despite funding, trade and geopolitical uncertainty.
Industrial Equipment outlook includes continued strong spot-beam lithography demand, early signs of multi-beam mask-writer recovery and solid single-beam inquiries.
Latest events from JEOL
- Net sales dropped 39.1% YoY to ¥24.5 billion, resulting in a net loss and negative segment profits.6951
Q1 2027 - Record net profit and share repurchase amid lower sales and business portfolio shift.6951
Q4 2026 - Revenue and profit fell, but financial stability and growth initiatives were maintained.6951
Q3 2026 - Vertical argon ion etching delivers uniform, high-resolution depth profiling with minimal roughness.6951
Status update - Sales and profits fell year-over-year, but Medical Equipment outperformed and dividends remain robust.6951
Q2 2026 - Strong quarterly growth in sales and profit, but full-year outlook signals a slight decline.6951
Q1 2026 - Strong sales growth and margin expansion drive upward revision to full-year outlook.6951
Q2 2025 - Revenue and profit surged in Q1 FY2025, led by robust equipment demand; outlook unchanged.6951
Q1 2025 - Record sales and profit, but lower net income and cautious outlook for next year.6951
Q4 2025